UBX vs. ONCT, ACST, BIOR, JAN, NNVC, ITRM, FBRX, LSTA, RNXT, and ENLV
Should you be buying Unity Biotechnology stock or one of its competitors? The main competitors of Unity Biotechnology include Oncternal Therapeutics (ONCT), Acasti Pharma (ACST), Biora Therapeutics (BIOR), JanOne (JAN), NanoViricides (NNVC), Iterum Therapeutics (ITRM), Forte Biosciences (FBRX), Lisata Therapeutics (LSTA), RenovoRx (RNXT), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical preparations" industry.
Unity Biotechnology (NASDAQ:UBX) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.
Unity Biotechnology presently has a consensus target price of $6.00, indicating a potential upside of 308.16%. Oncternal Therapeutics has a consensus target price of $28.33, indicating a potential upside of 220.88%. Given Unity Biotechnology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Unity Biotechnology is more favorable than Oncternal Therapeutics.
Unity Biotechnology has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.
29.5% of Unity Biotechnology shares are owned by institutional investors. Comparatively, 16.1% of Oncternal Therapeutics shares are owned by institutional investors. 4.9% of Unity Biotechnology shares are owned by insiders. Comparatively, 8.0% of Oncternal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Oncternal Therapeutics had 7 more articles in the media than Unity Biotechnology. MarketBeat recorded 15 mentions for Oncternal Therapeutics and 8 mentions for Unity Biotechnology. Unity Biotechnology's average media sentiment score of 1.06 beat Oncternal Therapeutics' score of 0.53 indicating that Unity Biotechnology is being referred to more favorably in the media.
Unity Biotechnology has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -3,160.73%. Unity Biotechnology's return on equity of -104.21% beat Oncternal Therapeutics' return on equity.
Unity Biotechnology received 144 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 66.28% of users gave Unity Biotechnology an outperform vote while only 31.87% of users gave Oncternal Therapeutics an outperform vote.
Oncternal Therapeutics has higher revenue and earnings than Unity Biotechnology. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than Unity Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Unity Biotechnology beats Oncternal Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Unity Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Unity Biotechnology Competitors List
Related Companies and Tools
